Life Science Investing Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Life Science Investing Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
